Ragnar Frisch Centre for Economic Research, Norway.
Ragnar Frisch Centre for Economic Research, Norway; Norwegian Institute of Public Health, Norway.
Int J Drug Policy. 2018 Jun;56:144-152. doi: 10.1016/j.drugpo.2018.01.019. Epub 2018 Feb 17.
Drug policy, whether for legal or illegal substances, is a controversial field that encompasses many complex issues. Policies can have effects on a myriad of outcomes and stakeholders differ in the outcomes they consider and value, while relevant knowledge on policy effects is dispersed across multiple research disciplines making integrated judgements difficult.
Experts on drug harms, addiction, criminology and drug policy were invited to a decision conference to develop a multi-criterion decision analysis (MCDA) model for appraising alternative regulatory regimes. Participants collectively defined regulatory regimes and identified outcome criteria reflecting ethical and normative concerns. For cannabis and alcohol separately, participants evaluated each regulatory regime on each criterion and weighted the criteria to provide summary scores for comparing different regimes.
Four generic regulatory regimes were defined: absolute prohibition, decriminalisation, state control and free market. Participants also identified 27 relevant criteria which were organised into seven thematically related clusters. State control was the preferred regime for both alcohol and cannabis. The ranking of the regimes was robust to variations in the criterion-specific weights.
The MCDA process allowed the participants to deconstruct complex drug policy issues into a set of simpler judgements that led to consensus about the results.
药物政策,无论是针对合法还是非法物质,都是一个充满争议的领域,涵盖了许多复杂的问题。政策可能对无数结果产生影响,而利益相关者在他们考虑和重视的结果上存在差异,同时,关于政策效果的相关知识分散在多个研究学科中,使得综合判断变得困难。
邀请了毒品危害、成瘾、犯罪学和药物政策方面的专家参加决策会议,以制定一种多标准决策分析(MCDA)模型来评估替代监管制度。参与者共同定义监管制度,并确定反映伦理和规范问题的结果标准。对于大麻和酒精分别,参与者根据每个标准评估每个监管制度,并对标准进行加权,以提供比较不同制度的综合得分。
定义了四种通用的监管制度:绝对禁止、非刑事化、国家控制和自由市场。参与者还确定了 27 个相关标准,这些标准被组织成七个主题相关的集群。国家控制是酒精和大麻的首选制度。在不同标准特定权重的变化下,制度的排名是稳健的。
MCDA 过程使参与者能够将复杂的药物政策问题分解为一组更简单的判断,从而就结果达成共识。